(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Wolfgang Fendler discussing PSMA-PET and PROMISE re-defining stage and risk in patients with prostate cancer.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the Poster presentation of poster 1988. Dr. Tanya Jindal presented on behalf of the UNITE study collaborators, exploring Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients with advanced urothelial carcinoma (aUC).

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a presidential symposium of practice-changing trials. Professor Silke Gillessen presented the initial results of EORTC-GUCG 1333/PEACE-3, a phase III trial of radium-223 plus enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castrate-resistant prostate cancer (mCRPC).

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the presentation of Poster 1971. Dr. Pol Servián presented the RUTIVAC-1 Study: a randomized, double-blind, placebo-controlled Phase I trial evaluating the immunomodulatory Effect of RUTI^® in individuals with High-Risk Non-Muscle-Invasive Bladder Cancer Treated with Intravesical BCG.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a presidential symposium of practice-changing trials. Professor Karim Fizazi discussed the results of EORTC-GUCG 1333/PEACE-3, a phase III trial of radium-223 plus enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castrate-resistant prostate cancer (mCRPC)

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the presentation of Poster 1601. Dr. Joaquin Mateo presented the first results from ZZFIRST. A randomized phase II trial of enzalutamide with or without talazoparib in metastatic hormone-naïve prostate cancer (mHNPC).

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the session Poster 1598 presentation. Dr. William K. Kelly presented the initial results from a dose expansion cohorts in a phase 1 study exploring Xaluritamig, a STEAP1 x CD3 XmAb 2+1 ImmuneTherapy, in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the session Poster 1599 presentation. Dr. Karim Fizazi presented the third interim analysis of PSMAfore exploring symptomatic skeletal events, health-related quality of life, and pain in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the session Biochemical failure post-local therapy: An opportunity for tailored treatment? Dr. Daniela E. Oprea-Lager discussed if PSMA PET could be a game changer for treatment decision-making in patients with biochemical failure post-local therapy.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the poster 1968 presentation. Dr. Jonathan E. Rosenberg presented the results of the EV-103 Study with five-year follow-up of first line Enfortumab Vedotin (EV) + Pembrolizumab in Cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC).

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to presentation of Poster 1691. Dr. Laurence Albiges presented the updated efficacy and safety results from CheckMate 67T evaluating subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC).

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the presentation of poster 1637. Dr. Neeraj Agarwal presented a post hoc analysis from both cohorts in TALAPRO-2 study, exploring the efficacy of talazoparib and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Bradley McGregor presented updated efficacy results from the Double Antibody Drug conjugate (DAD) phase I trial of sacituzumab govitecan plus enfortumab vedotin in the ≥2^nd line treatment setting for metastatic urothelial carcinoma patients.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a genitourinary cancers poster session. Dr. Sarmad Sadeghi presented the final results of a phase II double-blind, randomized trial of axitinib +/- PF 04518600, an OX40 antibody for metastatic renal cell carcinoma (RCC) patients with disease progression following anti-PD-1/L-1 therapy.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a genitourinary cancers poster session. Dr. Jason Redman presented the results of the Quick Efficacy Seeking Trial (QuEST1) trial of combination BN-brachyury (BNVax) + bintrafusp alfa + nogapendekin alfa inbakicept-pmln (N-803) in castrate-resistant prostate cancer.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Vincent Habouzit presented the results of a nationwide study evaluating factors associated with clinical and biologic responses in French patients receiving [¹⁷⁷Lu]Lu-PSMA-617 under France’s early access program.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a genitourinary cancers poster session. Dr. Evan Yu presented the results of ARROW, a multicenter randomized phase II trial of PSMA-targeted radioligand therapy with ¹³¹I-LNTH-1095 plus enzalutamide versus enzalutamide alone in chemotherapy-naïve metastatic castrate-resistant prostate cancer (mCRPC) patients with disease progression on abiraterone and positive piflufolastat F 18 scans.

(UroToday.com) The 2024 ESMO annual meeting included a session on urothelial carcinoma, featuring a presentation by Dr. Joshua Meeks discussing a prospective evaluation of BCG unresponsive bladder cancer carcinoma in situ (CIS) to identify genetic mechanisms of immunotherapy resistance and targeted therapy using an ultra-sensitive next-generation sequencing minimal residual disease assay.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Martina Buffoni presented the results of the BonEnza trial that evaluated total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation therapy (ADT) and enzalutamide +/- zoledronic acid.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Lisa Horvath presented the results of an ad hoc analysis of the ENZAMET trial (ANZUP 1304) evaluating the association between the lipid biomarker, PCPro, and clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients.